CytoDyn Inc. (BST:296)
Germany · Delayed Price · Currency is EUR 0.2300
0.00 (0.00%)
At close: Mar 19, 2026
CytoDyn Company Description
CytoDyn Inc., a clinical-stage biotechnology company, develops treatments for multiple therapeutic indications.
It is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19.
The company’s leronlimab is currently under phase 2 development for the treatment of micro-satellite stable colorectal cancer, and solid tumors in oncology, such as metastatic triple-negative breast cancer.
It has a collaboration with Creatv Bio. The company was formerly known as RexRay Corporation.
CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.
CytoDyn Inc.
| Country | United States |
| Founded | 2002 |
| Industry | Biological Products, Except Diagnostic Substances |
| Employees | 13 |
| CEO | Jacob Lalezari |
Contact Details
Address: 1111 Main Street Vancouver, Washington 98660 United States | |
| Phone | 360 980 8524 |
| Website | cytodyn.com |
Stock Details
| Ticker Symbol | 296 |
| Exchange | Stuttgart Stock Exchange |
| Stock Type | Common Stock |
| Fiscal Year | June - May |
| Reporting Currency | USD |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Jacob Lalezari | Chief Executive Officer |
| Robert Hoffman | Chief Financial Officer |
| Bernie Cunningham | Chief Operating Officer |